GW Pharmaceuticals PLC- (NASDAQ:GWPH) insider Douglas B. Snyder sold 5,424 shares of GW Pharmaceuticals PLC- stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $13.04, for a total value of $70,728.96. Following the sale, the insider now owns 73,740 shares in the company, valued at approximately $961,569.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Douglas B. Snyder also recently made the following trade(s):

  • On Tuesday, July 9th, Douglas B. Snyder sold 4,968 shares of GW Pharmaceuticals PLC- stock. The shares were sold at an average price of $14.42, for a total value of $71,638.56.

NASDAQ:GWPH traded up $2.01 during trading hours on Wednesday, reaching $152.86. 318,297 shares of the company’s stock were exchanged, compared to its average volume of 442,404. The company has a market capitalization of $4.55 billion, a P/E ratio of -14.48 and a beta of 2.25. GW Pharmaceuticals PLC- has a 12 month low of $90.14 and a 12 month high of $196.00. The company has a quick ratio of 7.59, a current ratio of 8.31 and a debt-to-equity ratio of 0.03. The business’s 50-day simple moving average is $164.38 and its two-hundred day simple moving average is $166.74.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.78) EPS for the quarter, topping analysts’ consensus estimates of ($1.74) by $0.96. GW Pharmaceuticals PLC- had a negative net margin of 101.45% and a negative return on equity of 38.09%. The firm had revenue of $72.04 million during the quarter, compared to analyst estimates of $37.28 million. During the same quarter last year, the business posted ($0.25) EPS. The company’s revenue was up 2096.3% on a year-over-year basis. As a group, sell-side analysts anticipate that GW Pharmaceuticals PLC- will post -3.84 earnings per share for the current fiscal year.

Several equities analysts have issued reports on GWPH shares. Zacks Investment Research upgraded GW Pharmaceuticals PLC- from a “hold” rating to a “strong-buy” rating and set a $192.00 target price on the stock in a research report on Monday, August 12th. Oppenheimer upped their target price on GW Pharmaceuticals PLC- from $234.00 to $239.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. CIBC upgraded GW Pharmaceuticals PLC- from a “market perform” rating to an “outperform” rating in a report on Tuesday, May 7th. Guggenheim reiterated a “buy” rating and issued a $222.00 price target (up from $186.00) on shares of GW Pharmaceuticals PLC- in a report on Tuesday, May 7th. Finally, JPMorgan Chase & Co. raised shares of GW Pharmaceuticals PLC- from a “market perform” rating to an “outperform” rating in a research report on Wednesday, May 8th. Two investment analysts have rated the stock with a sell rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $212.70.

Institutional investors have recently bought and sold shares of the stock. Osborn Williams & Donohoe LLC acquired a new stake in shares of GW Pharmaceuticals PLC- during the 1st quarter valued at $129,000. Marshall Wace LLP raised its holdings in GW Pharmaceuticals PLC- by 176.1% in the 1st quarter. Marshall Wace LLP now owns 11,866 shares of the biopharmaceutical company’s stock worth $2,000,000 after acquiring an additional 7,568 shares during the period. Exane Derivatives bought a new position in GW Pharmaceuticals PLC- in the 1st quarter worth $28,000. Park Avenue Securities LLC bought a new position in GW Pharmaceuticals PLC- in the 1st quarter worth $224,000. Finally, US Bancorp DE raised its holdings in GW Pharmaceuticals PLC- by 0.6% in the 1st quarter. US Bancorp DE now owns 11,683 shares of the biopharmaceutical company’s stock worth $1,969,000 after acquiring an additional 75 shares during the period. 80.94% of the stock is owned by hedge funds and other institutional investors.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

See Also: Understanding the different types of bonds

Insider Buying and Selling by Quarter for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.